Hydration Pharmaceuticals Co. Ltd. (HPC) AI Stock Analysis

• Market Cap: AU$2.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.21M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.36
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Food Distribution
• EPS (TTM): >-0.01
• Shares Outstanding: 430,800,930
• 10 Day Avg. Volume: 3,315,133
• 30 Day Avg. Volume: 1,207,806
• PEG Ratio: <0.01
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -0.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: AU$0.01 ▲(0.00% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

The score is primarily constrained by weak financial performance—volatile and declining revenue, structurally unprofitable operations, and persistent negative operating/free cash flow—implying ongoing funding risk despite low reported debt. Valuation is also hindered by a negative P/E and no dividend yield data. Technical and earnings-call/event inputs were not available to improve or reduce the assessment.

Positive Factors

Low Financial Leverage

Reported zero debt in 2024–2025 materially lowers solvency risk and gives management longer optionality to raise capital or restructure financing without servicing existing debt. Over 2–6 months this supports strategic flexibility for funding product development, marketing, or working capital needs.

Consumer Health / Hydration Focus

A concentrated product focus in hydration/electrolytes targets resilient consumer-health demand and repeat-purchase categories. Structurally, health and wellness trends support steady long-term consumption and brand building potential, which can enable margin recovery if distribution and marketing scale efficiently.

Demonstrated Occasional Profitability

The company produced a strong net profit margin in 2024, showing the business can achieve profitability under certain conditions. This indicates that with stabilized revenue or better cost control, operational levers exist to return to profit, providing a realistic pathway to durable improvement within months.

Negative Factors

Persistent Cash Burn

Consistent negative operating and free cash flow, with 2025 OCF worsening to ~-3.8M, implies the business cannot self-fund. Over a 2–6 month horizon this elevates funding risk, increases likelihood of external financing or dilution, and constrains investment in distribution, product development, or working capital.

Revenue Volatility and Recent Decline

Highly volatile revenue and a material decline in 2025 undermine predictability needed to achieve scale and operating leverage. Persistent top-line instability impairs long-term margin recovery and strategic planning, making sustainable growth and durable profitability harder to realize without structural changes.

Negative Gross Profit & Large Operating Losses

A negative gross profit and deep operating losses highlight that the core business is not covering direct costs, indicating structural margin issues. Without sustained gross margin recovery or a business-model reset, operating losses will continue to erode equity and limit ability to compete or invest over the medium term.

Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model

Company Description

Hydration Pharmaceuticals Co. Ltd. (HPC) is a company specializing in the development, manufacturing, and distribution of innovative hydration solutions. Operating within the health and wellness sector, HPC focuses on providing high-quality, scientifically-backed products designed to improve hydration and overall well-being. Their core product offerings include electrolyte-infused beverages, hydration powders, and supplements tailored to meet the needs of diverse consumer groups, including athletes, health enthusiasts, and individuals seeking enhanced hydration solutions.

How the Company Makes Money

HPC generates revenue primarily through the sale of its hydration products, which are distributed across various channels including retail stores, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include wholesale partnerships with retailers, online sales through the company's website and other online marketplaces, and subscriptions for regular product deliveries. Additionally, HPC may engage in strategic partnerships or collaborations with health and wellness brands to expand its market reach and enhance product offerings, contributing to its earnings.

Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview

Summary

Income statement and cash flow are very weak: revenue is volatile and fell in 2025, gross profit turned slightly negative, EBIT losses remain very large, and operating/free cash flow are consistently negative with worsening 2025 cash burn (~-3.8M). The main offset is the balance sheet’s low leverage (0 debt in 2024–2025), but equity and assets have been unstable (including negative equity in 2023), keeping financial risk elevated.

Income Statement

Revenue has been highly volatile and most recently fell sharply in 2025 (annual revenue down to ~2.6M from ~3.2M in 2024, with an extreme negative growth rate shown). Profitability is weak: 2025 gross profit turned slightly negative and operating losses remain very large (EBIT margin deeply negative), indicating the business is not covering its cost structure. While 2024 reported a strong net profit margin, it did not translate into operating profitability (EBIT remained very negative), suggesting earnings quality is mixed and results are not yet durable.

Balance Sheet

The balance sheet shows low financial leverage in the most recent two years (total debt reported at 0 in 2024–2025), which reduces solvency risk. However, equity has been unstable over time (including negative equity in 2023) and total assets have contracted materially versus prior years, pointing to balance-sheet volatility and potential dilution/asset runoff risk. Returns on equity are also inconsistent (very negative in 2025 after positive in 2024), reinforcing the lack of steady value creation.

Cash Flow

Cash generation is a major weakness: operating cash flow has been consistently negative across all reported years, and 2025 operating cash burn worsened to roughly -3.8M. Free cash flow is also persistently negative, indicating the business has not been self-funding and likely depends on external capital to sustain operations. Although free cash flow to net income appears near 1.0 in some years, this is not a positive signal here because both cash flow and (often) earnings are negative, and the core issue is ongoing cash burn.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	-235.84K	2.56M	3.20M	10.04M	9.10M	6.13M
Gross Profit	-248.26K	-27.42K	1.62M	5.39M	4.70M	2.79M
EBITDA	-3.91M	-3.26M	-3.91M	-7.46M	-10.52M	-6.08M
Net Income	4.34M	-2.96M	2.67M	-8.10M	-10.61M	-8.97M
Balance Sheet
Total Assets	3.93M	2.19M	5.00M	6.69M	10.39M	15.31M
Cash, Cash Equivalents and Short-Term Investments	2.11M	1.12M	3.22M	1.84M	4.69M	10.67M
Total Debt	0.00	0.00	0.00	3.89M	3.71M	0.00
Total Liabilities	1.22M	774.76K	2.25M	7.05M	6.41M	2.08M
Stockholders Equity	2.71M	1.42M	2.74M	-358.25K	3.98M	13.23M
Cash Flow
Free Cash Flow	-1.64M	-3.78M	-3.02M	-5.73M	-9.75M	-8.08M
Operating Cash Flow	-1.64M	-3.78M	-3.02M	-5.73M	-9.75M	-8.08M
Investing Cash Flow	0.00	0.00	9.44M	0.00	0.00	-2.15K
Financing Cash Flow	514.25K	833.93K	-3.63M	2.72M	4.08M	17.03M

Hydration Pharmaceuticals Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LDX	49 Neutral	AU$210.20M	-14.02	-111.23%	―	12.96%	40.81%
HPC	44 Neutral	AU$2.15M	-0.86	―	―	―	―
HXL	40 Underperform	AU$2.17M	-9.29	-28.49%	―	―	46.43%

Hydration Pharmaceuticals Co. Ltd. Corporate Events

Hydralyte North America Resets Around U.S. Core as Revenue Falls but Cost Base Shrinks

Hydralyte North America reported a 22.9% drop in FY2025 revenue to US$2.47 million as it deliberately narrowed channels and rationalised SKUs while exiting non‑U.S. operations to focus on a streamlined U.S.‑only business. The company posted a net loss attributable to members of US$2.86 million, reduced its loss from continuing operations to US$2.75 million through significant cost cuts, and ended the year with US$1.1 million in cash and no debt, albeit with net tangible assets per share falling to 0.3 cents.

Management executed an aggressive restructuring, cutting headcount to four full‑time equivalents during FY2025 and then to two after year‑end, shifting creative and marketing functions to external agencies to lower fixed overheads and improve flexibility. Looking ahead, Hydralyte plans to rebuild revenue from higher‑margin products, supported by redesigned Hydralyte PLUS packaging, upgraded manufacturing partners to improve quality and margins, and strategic initiatives such as potential capital raisings, partnerships and M&A to reinforce the balance sheet and support growth.

The most recent analyst rating on (AU:HPC) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Hydration Pharmaceuticals Co. Ltd. stock, see the AU:HPC Stock Forecast page.

Hydralyte USA Maintains Steady Sales as Inventory Restock and Cost Cuts Aim to Drive 2026 Growth

Hydralyte USA reported Q4 FY25 net sales of US$540,000, broadly in line with prior quarters but constrained by an out-of-stock situation in its Hydralyte Variety Pack following a strong sales uplift through emerging U.S. distributors such as Cardinal and Medline. The company expects restocking of this key product in early February 2026 to support stronger March-quarter sales and views the variety pack’s demand as a new growth vector for 2026. Newly launched products, particularly Hydralyte Plus Metabolic Support, are contributing up to US$10,000 in additional monthly revenue, reinforcing the company’s strategy of expanding into functional health categories. Operating cash outflows of US$619,000 reflect ongoing investments in marketing, inventory and sales partnerships, while further cost-cutting measures in U.S. operations are planned to improve quarterly cashflows. With a quarter-end cash balance of US$1.11 million, management is focused on maintaining liquidity and pursuing strategic options, including potential M&A, to enhance shareholder value and strengthen its U.S. market position.

The most recent analyst rating on (AU:HPC) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Hydration Pharmaceuticals Co. Ltd. stock, see the AU:HPC Stock Forecast page.

Hydration Pharmaceuticals Director Karafili Sees 500,000 Options Expire

The Hydration Pharmaceuticals Company Limited has reported a change in director Adem Karafili’s relevant interests following the expiry and cancellation of 500,000 unlisted options held indirectly through Ankara Holdings Pty Ltd as trustee structures he controls. After the expiry-driven cancellation, Karafili’s indirect holdings remain substantial, comprising 2,562,389 fully paid ordinary shares and a suite of unlisted options with varying exercise prices and maturities through 2029, signalling a modest simplification of his equity-linked incentives without altering his underlying shareholding base.

The most recent analyst rating on (AU:HPC) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Hydration Pharmaceuticals Co. Ltd. stock, see the AU:HPC Stock Forecast page.

Hydration Pharmaceuticals Options Lapse, Simplifying Capital Structure

Hydration Pharmaceuticals has announced the lapse of 46,612,138 listed options (HPCAU), which expired unexercised on 31 December 2025 and were scheduled to convert at an exercise price of A$0.07. The expiry of this large block of options results in a simplification of the company’s capital structure, removing a potential source of future equity dilution for existing shareholders and providing greater clarity on the current issued capital base.

The most recent analyst rating on (AU:HPC) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Hydration Pharmaceuticals Co. Ltd. stock, see the AU:HPC Stock Forecast page.